- Home
- IDYA vs ALRM Comparison
IDYA vs ALRM Comparison
Compare IDYA & ALRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IDYA | ALRM |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.4B |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | IDYA | ALRM |
|---|---|---|
| Price | $31.94 | $47.80 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 4 |
| Target Price | $51.21 | ★ $57.00 |
| AVG Volume (30 Days) | ★ 757.3K | 458.2K |
| Earning Date | 05-19-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.90 | 7.42 |
| EPS | N/A | ★ 2.46 |
| Revenue | $218,710,000.00 | ★ $1,011,187,000.00 |
| Revenue This Year | N/A | $5.03 |
| Revenue Next Year | $97.58 | $3.95 |
| P/E Ratio | ★ N/A | $19.81 |
| Revenue Growth | ★ 3024.43 | 7.59 |
| 52 Week Low | $13.45 | $43.00 |
| 52 Week High | $39.28 | $59.98 |
Technical Indicators
Market Signals| Indicator | IDYA | ALRM |
|---|---|---|
| Relative Strength Index (RSI) | 45.48 | 51.72 |
| Support Level | $29.15 | $45.85 |
| Resistance Level | $33.64 | $52.86 |
| Average True Range (ATR) | 1.47 | 1.65 |
| MACD | 0.10 | 0.39 |
| Stochastic Oscillator | 59.47 | 82.76 |
Price Performance
Historical ComparisonAbout IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About ALRM Alarm.com Holdings Inc.
Alarm.com Holdings Inc has a cloud-based platform that offers an expansive suite of IoT solutions addressing world-wide opportunities in the residential, multi-family, small business and enterprise commercial markets. It has two reportable segments: Alarm.com & Other. The Alarm.com segment represents the cloud-based Software platforms for intelligently connected property & related solutions. The other segment is focused on researching, developing & offering residential & commercial automation solutions & energy management products & services in adjacent markets. The majority of revenue is from the Alarm.com segment. The platform allows home & business owners to secure their properties and automate & control an array of connected devices.